Kailera Therapeutics Inc, a venture capital-backed enterprise with obesity assets in-licensed from China, has raised $625 million from an initial public offering on Nasdaq, one of the largest biotech IPOs in recent years. The funds will be used to advance the company’s lead product ribupatide, currently in global Phase 3 trials, as well as three other candidate obesity treatments that cover several mechanisms of action and methods of delivery.
The IPO results, announced on 16 April, come only six months after the company raised $600 million from a Series B financing, and less than two years from its launch on 1 October 2024. Kailera started corporate life with Series A funding of $400 million that was co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments. The same funders have been active in the company since that time. Kailera’s founding chief executive, Ron Renaud, is a serial entrepreneur, having led multiple biopharma companies, and been an advisor to Bain.
“With an increasing global population affected by obesity and limited options for those living with higher BMIs (body mass index), the need for effective treatment options has never been greater,” Mr Renaud said at the time of the Series B financing. Now, with IPO receipts of $625 million and existing cash resources and marketable securities, Kailera expects to cover its operating expenses into the second quarter of 2028.
While obesity drug developer Novo Nordisk A/S developed its lead weight-loss treatment in-house, Kailera in-licensed its assets from Jiangsu Hengrui Pharmaceuticals Co Ltd of China in May 2024. Kailera has exclusive rights for global development and commercialisation of four assets, including ribupatide, for geographies outside of China, and its immediate neighbours.
Ribupatide is a GLP-1/GIP receptor dual agonist peptide which activates receptors to improve blood sugar control and promote weight loss. The method of delivery is by subcutaneous injection once per week. The same drug is being developed for oral delivery once per day. The portfolio also includes an oral GLP-1 receptor agonist and an injectable GLP-1/GIP glucagon receptor tri-agonist. Receipts from the IPO and other cash reserves will largely go to the injectable and oral ribupatide products, according to the company’s S-1 filing with the US Securities and Exchange Commission.
Copyright 2026 Evernow Publishing Ltd